Enhanced synthesis of l-threo-3,4-dihydroxyphenylserine by high-density whole-cell biocatalyst of recombinant L-threonine aldolase from Streptomyces avelmitilis

  • Sang Ho Baik*
  • , Hideki Yoshioka
  • *Corresponding author for this work

Research output: Contribution to journalJournal articlepeer-review

Abstract

L-threo-3,4-Dihydroxyphenylserine (DOPS) is a chiral unnatural β-hydroxy amino acid used for the treatment of Parkinson disease. We developed a continuous bioconversion system for DOPS production that uses whole-cell biocatalyst of recombinant Escherichia coli expressing l-threonine aldolase (l-TA) genes cloned from Streptomyces avelmitilis MA-4680. Maximum conversion rates were observed at 2 M glycine, 145 mM 3,4-dihydroxybenzaldehyde, 0.75% Triton-X, 5 g E. coli cells/l, pH 6.5 and 10°C. In the optimized condition, overall productivity was 8 g/l, which represents 40 times the synthesis yield possible with no optimization of conditions.

Original languageEnglish
Pages (from-to)443-448
Number of pages6
JournalBiotechnology Letters
Volume31
Issue number3
DOIs
StatePublished - 2009.03

Keywords

  • β-Hydroxy amino acid
  • L-threo-2,3-Dihydroxyphenylserine
  • L-Threonine aldolase
  • Whole-cell conversion

Quacquarelli Symonds(QS) Subject Topics

  • Engineering - Chemical
  • Biological Sciences

Fingerprint

Dive into the research topics of 'Enhanced synthesis of l-threo-3,4-dihydroxyphenylserine by high-density whole-cell biocatalyst of recombinant L-threonine aldolase from Streptomyces avelmitilis'. Together they form a unique fingerprint.

Cite this